Medicinal Chemicals & Botanical Products · SIC 2833

FITLIFE BRANDS, INC.

FTLF

Watch

Latest revenue

$25.3M

as of 2026-03-31

Latest net income

$1.7M

as of 2026-03-31

Net margin

6.8%

as of 2026-03-31

Price · 5Y

+16.6% / yr 2.8 pts / yr vs S&P 500 114.8% total
Compare:

Live market

delayed ≤15 min
$10.07
2.89%
Market cap
$94.6M
Enterprise value
$94.6M
P/E (trailing)
14.9×
Forward P/E
P/B
Dividend yield
0.0%
52-wk high
$20.98
52-wk low
$8.67
Beta
Shares out
9.4M

5-year trend

What this company does

AI

ITEM 1. BUSINESS As used in this Annual Report, “we”, “us”, “our”, “FitLife”, “FitLife Brands”, the “Company” or “our company” refers to FitLife Brands, Inc. and all of its subsidiaries. Overview FitLife Brands, Inc. (the “Company”) is a national provider of innovative and proprietary nutritional supplements for health-conscious consumers marketed under the following brand names: (i) NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Nutrology, and Metis Nutrition (together, “NDS Products”); and (ii) iSatori, BioGenetic Laboratories, and Energize (together, the "iSatori Products"). The Company distributes the NDS Products principally through franchised General Nutrition Centers, Inc. (“GNC”)…

AI summary unavailable — showing raw filing excerpt

Generated from FTLF's filing dated 2023-03-24

Key risks

AI

ITEM 1A - Risk Factors An investment in our securities involves a high degree of risk. You should carefully consider the following information about these risks, together with the other information contained in this Annual Report, before investing in our securities. If any of the events anticipated by the risks described below occur, our results of operations and financial condition could be adversely affected, which could result in a decline in the market price of our securities, causing you to lose all or part of your investment. Risk Factors Relating to our Business and Industry The Company was profitable during the years ended December 31, 2022 and 2021. However, we may not be able to…

AI summary unavailable — showing raw filing excerpt

Generated from FTLF's filing dated 2023-03-24

Profitability

Gross margin

38.6%

11.3%

Operating margin

12.4%

39.3%

Net margin

7.8%

44.3%

Return on equity

14.5%

41.7%

Return on assets

5.9%

61.2%

Leverage

Debt / equity

1.44×

131.6%

Long-term debt / equity

0.75×

218.1%

Debt / assets

59.0%

54.0%

Earnings tracker

QuarterRevenueYoYNet incomeYoYNet margin

Q1 2026

2026-03-31

$25.3M+58.9%$1.7M-14.8%6.8%

Q4 2025

2025-12-31

$25.9M+72.6%$1.6M-20.8%6.3%

Q3 2025

2025-09-30

$23.5M+47.0%$921.0K-56.7%3.9%

Q2 2025

2025-06-30

$16.1M-4.7%$1.7M-33.5%10.8%

Q1 2025

2025-03-31

$15.9M-3.7%$2.0M-6.6%12.7%

Q4 2024

2024-12-31

$15.0M$2.1M13.8%

Q3 2024

2024-09-30

$16.0M+14.9%$2.1M+25.4%13.3%

Q2 2024

2024-06-30

$16.9M+14.7%$2.6M+33.8%15.5%

Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.

Industry trend

Medicinal Chemicals & Botanical Products · SIC 2833

No data yet for industry average

Your notes

Keep private notes on FTLF — thesis, target price, catalysts to watch.

Visible only to you. Never shared. Never used to train AI.

Sign in to write a note

Insider activity

Insider buying

$61.7K

Insider selling

$0

Net activity

+$61.7K

Distinct insiders

3

Open-market trades over the last 365 days.

Recent transactions

DateInsiderTypeSharesPriceValue
2026-04-10

Matthew Lingenbrink

Director

Purchase3,000$9.76$29.3K
2026-04-10

Grant Robert Dawson

Director

Purchase3,000$9.98$29.9K
2026-01-15

Seth Yakatan

Director

Purchase164$15.36$2.5K

Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.

Who owns FTLF

Institutional value

$6.9M

Total shares held

487.3K

Distinct holders

27

-16 vs prior

As of

2026-03-31

Prior: 2025-12-31

Filers with $100M+ AUM disclose holdings 45 days after quarter end.

Top institutional holders

#ManagerSharesValueQoQ changeAction
1BlackRock, Inc.157.4K$2.2M-1.8K (-1.1%)Trimmed
2VANGUARD CAPITAL MANAGEMENT LLC154.6K$2.2MNew
3Mink Brook Asset Management LLC28.6K$406.7KNew
4VANGUARD FIDUCIARY TRUST CO24.9K$354.2KNew
5VANGUARD PORTFOLIO MANAGEMENT LLC23.5K$333.5KNew
6STIFEL FINANCIAL CORP20.0K$283.7K-20.4K (-50.6%)Trimmed
7BARD ASSOCIATES INC20.0K$283.5K+2.4K (+13.5%)Added
8DIMENSIONAL FUND ADVISORS LP17.1K$242.3K-2.8K (-14.0%)Trimmed
9O'SHAUGHNESSY ASSET MANAGEMENT, LLC13.3K$189.2K-2.9K (-17.7%)Trimmed
10Steward Partners Investment Advisory, LLC6.4K$91.2K+2.9K (+84.7%)Added
11RHUMBLINE ADVISERS4.9K$69.5K+64 (+1.3%)Added
12NEW YORK STATE COMMON RETIREMENT FUND4.5K$63.4K+0 (+0.0%)No change
13UBS Group AG3.1K$43.9K+191 (+6.6%)Added
14Vanguard Global Advisers, LLC2.1K$30.0KNew
15JPMORGAN CHASE & CO1.6K$22.6K-406 (-20.4%)Trimmed
16BNP PARIBAS FINANCIAL MARKETS1.5K$21.1K-38 (-2.5%)Trimmed
17WELLS FARGO & COMPANY/MN1.4K$20.1K-2.9K (-66.8%)Trimmed
18Police & Firemen's Retirement System of New Jersey1.0K$14.5K+0 (+0.0%)No change
19Ameritas Investment Partners, Inc.399$5.7K+0 (+0.0%)No change
20Legal & General Group Plc389$5.5K-78 (-16.7%)Trimmed

Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.

Top questions investors are asking

Coming once FTLF's latest filing finishes processing.